Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

News Release

 View printer-friendly version

Charles River Laboratories Presents 25 Scientific Posters at Neuroscience 2015

CHICAGO--(BUSINESS WIRE)--Oct. 19, 2015-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of leading Central Nervous System (CNS) researchers is presenting 25 posters at Neuroscience 2015, the annual meeting of the Society for Neuroscience (SfN). The meeting, which has a lengthy history of scientific engagement and excellence, is taking place this week at McCormick Place in Chicago, Illinois.

“This is an exciting time for neuroscience research and we are pleased to be at the forefront,” said Patrick Sweeney, Managing Director of Charles River Discovery Services. “This year, we have partnered with several clients to present our latest research findings and are hosting two scientific events that will address the current thinking in the areas of orphan drug development and disorders associated with protein misfolding. Neuroscience 2015 offers our experts the opportunity to collaborate with top scientists from across the globe as we work to advance research in this rapidly transforming field.”

Among the posters the Charles River team will present are tools, applications, and assays for research targeting Huntington’s, Alzheimer’s, Parkinson’s, Multiple Sclerosis, Autism, Depression and other neurological disorders. Noteworthy examples include:

  • A collaboration profiling efforts towards the development of a PET tracer for aggregated α-synuclein, which is thought to play a role in the pathology of Parkinson’s disease. (Studies Towards the Development of a PET Tracer for Aggregated α-Synuclein)
  • A collaboration to establish optimal parameters for the use of BOLD contrast-based phMRI as a tool in CNS disease research. (Blood Oxygenation Level-Dependent (BOLD) Contrast-Based Pharmacological MRI)
  • Behavioral characterization of a genetically modified model for use in development of therapies targeting autism spectrum disorder. (Characterization of BTBR T+tf/J Model for Autism Spectrum Disorder)
  • A collaboration to assess the chronic social defeat assay for alterations in an enzyme thought to contribute to depressive symptoms in humans, and the response to its inhibition. (Chronic Social Defeat Assay for Assessing Anti-Depression Therapies)

A full schedule of Charles River’s poster presentations is available to download, and reprints of each poster are available in Charles River’s booth (#1415) during the conference. Additionally, CNS experts are available for meetings with those interested in discussing neuroscience research. Throughout the conference, Charles River will be providing live updates on the Eureka Blog, including reviews of scientific sessions and input on the research being presented.

To learn more about Charles River’s presence at SfN’s Neuroscience 2015, please visit our website.

About the Society for Neuroscience

The Society for Neuroscience is the world’s largest organization of scientists and physicians devoted to understanding the brain and nervous system. The nonprofit organization, founded in 1969, now has nearly 40,000 members in more than 90 countries and 130 chapters worldwide.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Source: Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.
Investor Contact:
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
susan.hardy@crl.com
or
Media Contact:
Amy Cianciaruso, 781-222-6168
Executive Director, Public Relations
amy.cianciaruso@crl.com

Featured Report

2018 Annual Report (PDF)

Investor Hotline

877-567-6CRL (6275)